gsk2236805
Small moleculeexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 3, 2010 (NCT01277692)
Timeline
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2236805
- gsk2236805
- gsk2336805
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02018536 | Phase 1 | Oct 1, 2013 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01827657 | Phase 1 | May 28, 2013 | GlaxoSmithKline |
| NCT01724086 | Phase 2 | Oct 1, 2012 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01648140 | Phase 2 | Aug 1, 2012 | GlaxoSmithKline, PPD |
| NCT01458054 | Phase 1 | Sep 1, 2011 | GlaxoSmithKline |
| NCT01424540 | Phase 1 | Sep 1, 2011 | GlaxoSmithKline |
| NCT01439373 | Phase 2 | Jul 1, 2011 | GlaxoSmithKline, PPD |
| NCT01277692 | Phase 1 | Nov 3, 2010 | GlaxoSmithKline |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2010 |
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 2 | 2012 |
| Johnson and Johnson | For profit | 2 | 2 | 2 | 2012 |
| PPD | For profit | 2 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1